239 related articles for article (PubMed ID: 12699387)
21. Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethyl-benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT).
Springer CJ; Antoniw P; Bagshawe KD; Wilman DE
Anticancer Drug Des; 1991 Nov; 6(5):467-79. PubMed ID: 1764165
[TBL] [Abstract][Full Text] [Related]
22. Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.
Blakey DC; Davies DH; Dowell RI; East SJ; Burke PJ; Sharma SK; Springer CJ; Mauger AB; Melton RG
Br J Cancer; 1995 Nov; 72(5):1083-8. PubMed ID: 7577451
[TBL] [Abstract][Full Text] [Related]
23. Development of triazene prodrugs for ADEPT strategy: new insights into drug delivery system based on carboxypeptidase G2 activation.
Capucha V; Mendes E; Francisco AP; Perry MJ
Bioorg Med Chem Lett; 2012 Nov; 22(22):6903-8. PubMed ID: 23041157
[TBL] [Abstract][Full Text] [Related]
24. ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts.
Blakey DC; Burke PJ; Davies DH; Dowell RI; East SJ; Eckersley KP; Fitton JE; McDaid J; Melton RG; Niculescu-Duvaz IA; Pinder PE; Sharma SK; Wright AF; Springer CJ
Cancer Res; 1996 Jul; 56(14):3287-92. PubMed ID: 8764123
[TBL] [Abstract][Full Text] [Related]
25. A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy.
Marais R; Spooner RA; Stribbling SM; Light Y; Martin J; Springer CJ
Nat Biotechnol; 1997 Dec; 15(13):1373-7. PubMed ID: 9415889
[TBL] [Abstract][Full Text] [Related]
26. Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2.
Springer CJ; Antoniw P; Bagshawe KD; Searle F; Bisset GM; Jarman M
J Med Chem; 1990 Feb; 33(2):677-81. PubMed ID: 2299634
[TBL] [Abstract][Full Text] [Related]
27. Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy.
Friedlos F; Denny WA; Palmer BD; Springer CJ
J Med Chem; 1997 Apr; 40(8):1270-5. PubMed ID: 9111301
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and biological evaluation of novel pyrrolo[2,1-c][1,4]benzodiazepine prodrugs for use in antibody-directed enzyme prodrug therapy.
Masterson LA; Spanswick VJ; Hartley JA; Begent RH; Howard PW; Thurston DE
Bioorg Med Chem Lett; 2006 Jan; 16(2):252-6. PubMed ID: 16290933
[TBL] [Abstract][Full Text] [Related]
29. Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial.
Martin J; Stribbling SM; Poon GK; Begent RH; Napier M; Sharma SK; Springer CJ
Cancer Chemother Pharmacol; 1997; 40(3):189-201. PubMed ID: 9219501
[TBL] [Abstract][Full Text] [Related]
30. Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue.
Monks NR; Blakey DC; Curtin NJ; East SJ; Heuze A; Newell DR
Br J Cancer; 2001 Sep; 85(5):764-71. PubMed ID: 11531265
[TBL] [Abstract][Full Text] [Related]
31. Novel prodrugs of alkylating agents derived from 2-fluoro- and 3-fluorobenzoic acids for antibody-directed enzyme prodrug therapy.
Springer CJ; Niculescu-Duvaz I; Pedley RB
J Med Chem; 1994 Jul; 37(15):2361-70. PubMed ID: 8057284
[TBL] [Abstract][Full Text] [Related]
32. Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT).
Monks NR; Calvete JA; Curtin NJ; Blakey DC; East SJ; Newell DR
Br J Cancer; 2000 Jul; 83(2):267-9. PubMed ID: 10901381
[TBL] [Abstract][Full Text] [Related]
33. Adenovirus vector-mediated delivery of the prodrug-converting enzyme carboxypeptidase G2 in a secreted or GPI-anchored form: High-level expression of this active conditional cytotoxic enzyme at the plasma membrane.
Cowen RL; Williams JC; Emery S; Blakey D; Darling JL; Lowenstein PR; Castro MG
Cancer Gene Ther; 2002 Nov; 9(11):897-907. PubMed ID: 12386828
[TBL] [Abstract][Full Text] [Related]
34. A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs.
Spooner RA; Friedlos F; Maycroft K; Stribbling SM; Roussel J; Brueggen J; Stolz B; O'Reilly T; Wood J; Matter A; Marais R; Springer CJ
Br J Cancer; 2003 May; 88(10):1622-30. PubMed ID: 12771932
[TBL] [Abstract][Full Text] [Related]
35. Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma.
Napier MP; Sharma SK; Springer CJ; Bagshawe KD; Green AJ; Martin J; Stribbling SM; Cushen N; O'Malley D; Begent RH
Clin Cancer Res; 2000 Mar; 6(3):765-72. PubMed ID: 10741695
[TBL] [Abstract][Full Text] [Related]
36. Radiosynthesis of 4-[(2-chloroethyl)(2-[(11)C]ethyl)amino]-phenoxycarbonyl-l-glutamic acid a half mustard prodrug as a potential probe for imaging antibody- and gene-directed enzyme prodrug therapy with positron emission tomography.
Malik N; Luthra SK; Burke P; Price PM; Aboagye EO; Latigo J; Zhao Y; Brady F
Appl Radiat Isot; 2004 Jun; 60(6):825-34. PubMed ID: 15110346
[TBL] [Abstract][Full Text] [Related]
37. Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation.
Helsby NA; Wheeler SJ; Pruijn FB; Palmer BD; Yang S; Denny WA; Wilson WR
Chem Res Toxicol; 2003 Apr; 16(4):469-78. PubMed ID: 12703963
[TBL] [Abstract][Full Text] [Related]
38. Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185.
Eccles SA; Court WJ; Box GA; Dean CJ; Melton RG; Springer CJ
Cancer Res; 1994 Oct; 54(19):5171-7. PubMed ID: 7923136
[TBL] [Abstract][Full Text] [Related]
39. Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy.
Hu L; Yu C; Jiang Y; Han J; Li Z; Browne P; Race PR; Knox RJ; Searle PF; Hyde EI
J Med Chem; 2003 Nov; 46(23):4818-21. PubMed ID: 14584930
[TBL] [Abstract][Full Text] [Related]
40. Nitroarylmethylcarbamate prodrugs of doxorubicin for use with nitroreductase gene-directed enzyme prodrug therapy.
Hay MP; Wilson WR; Denny WA
Bioorg Med Chem; 2005 Jun; 13(12):4043-55. PubMed ID: 15911317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]